HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
NDUFA13
NADH:ubiquinone oxidoreductase subunit A13
Chromosome 19 Β· 19p13.11
NCBI Gene: 51079Ensembl: ENSG00000186010.20HGNC: HGNC:17194UniProt: Q9P0J0
169PubMed Papers
22Diseases
3Drugs
6Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneTransporter
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein bindingnucleoplasmcytoplasmmitochondrionmitochondrial complex I deficiency, nuclear type 28type 2 diabetes mellitusdiabetes mellitusmitochondrial complex I deficiency
✦AI Summary

NDUFA13 is an accessory subunit of mitochondrial Complex I (NADH dehydrogenase), essential for electron transfer from NADH to ubiquinone in the respiratory chain 1. Unlike catalytic subunits, NDUFA13 functions structurally to stabilize Complex I assembly and integrity 2. Beyond its respiratory role, NDUFA13 participates in interferon/retinoic acid-induced apoptosis and negatively regulates STAT3-mediated transcription 3, with proposed involvement in intestinal immune responses. Biallelic NDUFA13 mutations cause mitochondrial complex I deficiency, nuclear type 28 (OMIM), presenting with severe neurodevelopmental impairment, spasticity, cerebellar ataxia, oculomotor abnormalities, and characteristic bilateral substantia nigra T2 hyperintensities 425. Pathogenic variants reduce Complex I enzymatic activity and protein abundance, impairing mitochondrial respiration and ATP production 26. NDUFA13 also regulates mitochondrial oxidative stress in angiotensin II-induced cardiac remodeling through the SGK3-NLRP3 pathway 7. Recent studies identify NDUFA13 as a prognostic biomarker in multiple myeloma and metabolic dysfunction-associated steatotic liver disease, linking its function to broader metabolic and immune homeostasis 89. Clinical severity correlates with specific mutation types, with missense variants affecting the hydrophilic-membrane arm junction.

Sources cited
1
NDUFA13 is an accessory subunit of Complex I not directly involved in catalysis; ubiquinone serves as the electron acceptor
PMID: 27626371
2
First germinal NDUFA13 mutation causes early hypotonia, dyskinesia, sensorial deficiencies, drastic Complex I activity decrease, and CI holoenzyme instability
PMID: 25901006
3
NDUFA13 involvement in apoptosis and STAT3 signaling regulation in relation to autophagy pathways
PMID: 25951043
4
NDUFA13 mutations present with moderate-to-severe neurodevelopmental syndrome featuring oculomotor abnormalities, spasticity, ataxia, bilateral substantia nigra lesions, and optic nerve atrophy
PMID: 39963288
5
NDUFA13 variants cause Leigh syndrome with isolated Complex I deficiency, spastic tetraparesis, and reduced NDUFA13 protein/Complex I levels
PMID: 32722639
6
NDUFA13 pathogenic variants impair Complex I enzyme activity and mitochondrial function in combined metabolic disorder presentation
PMID: 40358162
7
NDUFA13 mediates mitochondrial oxidative stress in angiotensin II-induced cardiac remodeling through SGK3-NLRP3-IL-1Ξ² pathway
PMID: 39158709
8
NDUFA13 identified as prognostic gene in multiple myeloma involving mitochondrial function and programmed cell death pathways
PMID: 39726602
9
NDUFA13 identified as comorbid gene in triglyceride-glucose/metabolic dysfunction-associated steatotic liver disease causal pathway
PMID: 41056021
Disease Associationsβ“˜22
mitochondrial complex I deficiency, nuclear type 28Open Targets
0.65Moderate
type 2 diabetes mellitusOpen Targets
0.62Moderate
diabetes mellitusOpen Targets
0.60Moderate
mitochondrial complex I deficiencyOpen Targets
0.50Moderate
Thyroid Gland Oncocytic Follicular CarcinomaOpen Targets
0.43Moderate
polycystic ovary syndromeOpen Targets
0.42Moderate
obesityOpen Targets
0.42Moderate
gestational diabetesOpen Targets
0.41Moderate
Insulin resistanceOpen Targets
0.40Moderate
prediabetes syndromeOpen Targets
0.40Weak
metabolic syndromeOpen Targets
0.39Weak
type 1 diabetes mellitusOpen Targets
0.39Weak
Disorder of lipid metabolismOpen Targets
0.38Weak
agingOpen Targets
0.37Weak
follicular thyroid carcinomaOpen Targets
0.37Weak
prostate cancerOpen Targets
0.37Weak
COVID-19Open Targets
0.36Weak
abnormal glucose toleranceOpen Targets
0.36Weak
metabolic diseaseOpen Targets
0.35Weak
breast cancerOpen Targets
0.35Weak
Hurthle cell thyroid carcinomaUniProt
Mitochondrial complex I deficiency, nuclear type 28UniProt
Pathogenic Variants6
NM_015965.7(NDUFA13):c.170G>A (p.Arg57His)Likely pathogenic
Mitochondrial complex I deficiency|Mitochondrial complex I deficiency, nuclear type 28|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 57
NM_015965.7(NDUFA13):c.94+1G>ALikely pathogenic
Hurthle cell carcinoma of thyroid|Mitochondrial complex I deficiency, nuclear type 28|Melanoma
β˜…β˜†β˜†β˜†2023
NM_015965.7(NDUFA13):c.44dup (p.Tyr16fs)Likely pathogenic
Mitochondrial complex I deficiency, nuclear type 28|Hurthle cell carcinoma of thyroid
β˜…β˜†β˜†β˜†2022β†’ Residue 16
NM_015965.7(NDUFA13):c.194del (p.Phe65fs)Pathogenic
Decreased activity of mitochondrial complex I|Mitochondrial complex I deficiency, nuclear type 28
β˜†β˜†β˜†β˜†2024β†’ Residue 65
NM_015965.7(NDUFA13):c.107T>C (p.Leu36Pro)Pathogenic
Decreased activity of mitochondrial complex I|Mitochondrial complex I deficiency, nuclear type 28
β˜†β˜†β˜†β˜†2024β†’ Residue 36
NM_015965.7(NDUFA13):c.15G>C (p.Lys5Asn)Pathogenic
Hurthle cell carcinoma of thyroid
β˜†β˜†β˜†β˜†2005β†’ Residue 5
View on ClinVar β†—
Drug Targets3
ME-344Phase I/II
Mitochondrial complex I (NADH dehydrogenase) inhibitor
breast cancer
METFORMINApproved
Mitochondrial complex I (NADH dehydrogenase) inhibitor
diabetes mellitus
METFORMIN HYDROCHLORIDEApproved
Mitochondrial complex I (NADH dehydrogenase) inhibitor
type 2 diabetes mellitus
Related Genes
ATP5MEProtein interaction100%ATP5PFProtein interaction100%BLVRBProtein interaction100%COX5BProtein interaction100%COX6A2Protein interaction100%COX6B1Protein interaction100%
Tissue Expression6 tissues
Brain
100%
Liver
90%
Ovary
49%
Lung
46%
Bone Marrow
15%
Heart
9%
Gene Interaction Network
Click a node to explore
NDUFA13ATP5MEATP5PFBLVRBCOX5BCOX6A2COX6B1
PROTEIN STRUCTURE
Preparing viewer…
PDB5XTB Β· 3.40 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.30LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.87 [0.59–1.30]
RankingsWhere NDUFA13 stands among ~20K protein-coding genes
  • #2,629of 20,598
    Most Researched169 Β· top quartile
  • #569of 1,025
    FDA-Approved Drug Targets2
  • #3,322of 5,498
    Most Pathogenic Variants6
  • #13,691of 17,882
    Most Constrained (LOEUF)1.30
Genes detectedNDUFA13
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
The role of STAT3 in autophagy.
PMID: 25951043
Autophagy Β· 2015
1.00
2
Mitochondria-associated programmed cell death: elucidating prognostic biomarkers, immune checkpoints, and therapeutic avenues in multiple myeloma.
PMID: 39726602
Front Immunol Β· 2024
0.90
3
Gene biomarker prediction in glioma by integrating scRNA-seq data and gene regulatory network.
PMID: 34863158
BMC Med Genomics Β· 2021
0.84
4
Complex Metabolomic Changes in a Combined Defect of Glycosylation and Oxidative Phosphorylation in a Patient with Pathogenic Variants in
PMID: 40358162
Cells Β· 2025
0.80
5
SGK3 deficiency in macrophages suppresses angiotensin II-induced cardiac remodeling via regulating Ndufa13-mediated mitochondrial oxidative stress.
PMID: 39158709
Cell Mol Life Sci Β· 2024
0.70